The predominant effects of the sympathetic innervation of the lower urinary tract in man are mediation of contraction of the bladder base and the urethra and inhibition of the parasympathetic pathways at spinal and ganglion levels. Sympathetic tone also mediates the contractility of smooth muscle ®bres in the prostatic stroma, and it has an important role in maintaining the penis in a¯accid state and in ejaculation. In the detrusor muscle of most species, b-adrenoceptors (b-ARs) mediating relaxation normally dominate over a-ARs mediating contraction, and the effect of noradrenaline (NA) is relaxation. The human detrusor is able to express b 1 -, b 2 -and b 3 -ARs and stimulation of b 3 -ARs causes relaxation. Low, but reproducible expression of a 1 -ARs (a 1a and a 1d ) has been found in human detrusor muscle, but the a 1 -AR subtypes mediating contraction have not been established. The sympathetic pathways to the penis may mediate antierectile as well as erectile effects. Although a 1 and a 2 -ARs have been demonstrated in human corpus cavernosum tissue, available information supports the view of a functional predominance of a 1 -ARs. The human vas deferens also has an important adrenergic innervation and a 1A -ARs seem to mediate contraction.
Introduction
The urogenital tract has a complex central nervous and peripheral regulation. Three different efferent systems Ð the parasympathetic, the sympathetic and the somatic Ð respond to the input from sensory nerves to control micturition as well as erectile function and ejaculation. Following is a brief review focusing on the role of sympathetic nervous pathways, adrenergic innervation and receptor functions in micturition and sexual function.
Bladder and urethra
During ®lling of the bladder there is an ongoing, tonic sympathetic activity keeping the out¯ow region closed.
There is also activity in the somatic pathways to the striated urethral muscle and to the pelvic¯oor, but none in the parasympathetic pathways. 1, 2 Differences exist in the sympathetic innervation between the different parts of the lower urinary tract and also between males and females. 3 Unlike in the female, the male bladder neck has a very rich noradrenergic innervation. However, the bladder dome of both sexes has a sparse adrenergic innervation.
In isolated detrusor muscle from both sexes, noradrenaline (NA) is released in response to electrical stimulation of the nerves. 4 The normal response to NA is relaxation, since the number of b-adrenoceptors (b-ARs) is at least 20 ± 30 times higher than that of a-ARs. The human detrusor is able to express b 1 -, b 2 -as well as b 3 -ARs. The subtype most important for relaxation seems to be the b 3 -AR. 5 To investigate the a-AR function in bladder smooth muscle, drugs with selective effect on a-ARs must be used. It has been shown by several investigators that in the normal human detrusor, drugs selectively stimulating a-ARs have a small and variable contractile effect. This is particularly characteristic for the human detrusor. However, there are reports that the importance of a-ARs for contraction of the human bladder smooth muscle may change in, for example, out¯ow obstruction, neurogenic bladders and idiopathic bladder instability. 4 Perlberg and Caine 6 have shown that in patients with bladder hypertrophy and symptoms of benign prostatic hyperplasia (BPH), b-AR mediated relaxation was changed to an a-AR mediated contraction in 23% of the patients. They suggested that this could be a factor contributing to the storage symptoms of BPH. However, Smith and Chapple 7 found that only ®ve out of 72 strips from obstructed unstable bladders responded to the selective a 1 -AR agonist phenylephrine. Thus the role of peripheral a 1 -ARs in contraction in the obstructed bladder has not yet been resolved, nor has the subtype mediating contractile effects. Among the high af®nity receptors for prazosin that have been cloned and pharmacologically characterized, only a 1a and a 1d mRNA seem to be expressed in the human bladder. 8 The total a 1 -AR expression was low (6.3 AE 1.0 fentomol/mg), but reproducible. The ratio of the subtypes a 1d to a 1a was 66 : 34, with no expression of a 1b . 8 This is in contrast to what has been found in the human prostate. 9 The fact that drugs acting selectively on prostatic a 1 -ARs may have little effect on lower urinary tract symptoms (LUTS) can theoretically be explained if they did not block the a 1 -ARs of the bladder. Considering the doubtful functional importance of the bladder a 1 -ARs, this seems unlikely.
It has been assumed that excessive sympathetic activity, by causing functional obstruction via contraction of prostatic and urethral smooth muscle, may contribute to the storage symptoms of BPH. 9 If this is the case, a model of increased sympathetic activity should be useful for study of the role of the sympathetic nervous system in the pathogenesis of LUTS. Such a model may be the spontaneously hypertensive rat (SHR). 10 The SHR has an increased noradrenergic bladder innervation, an increased voiding frequency and bladder overactivity. 11 The total number of noradrenergic nerves in the different parts of the bladder Ð the base, the body and the dome Ð is increased and so is the NA content of the bladder. The voiding frequency is increased signi®cantly without any change in total urine output, which means that each individual void is decreased compared with controls (Wistar Kyoto rats, WKY). Urodynamic studies revealed that SHR have a pronounced bladder overactivity, which can explain the increased voiding frequency. 12 Whereas the WKY rats have a regular contraction frequency during continuous cystometry, the SHR show both micturition and non-micturition contractions. To investigate whether or not the peripheral adrenergic system was involved in pathogenesis of the bladder overactivity, SHR were treated with 6-hydroxydopamine in order to chemically destroy the noradrenergic nerves. In these rats, bladder overactivity was maintained as demonstrated by continuous cystometry [personal observation]. Furthermore, a 1 -AR antagonists injected intraarterially near the bladder did not abolish the bladder overactivity. On the other hand, when given intrathecally, the same amount of a 1 -antagonist normalized micturition. It may therefore be concluded that the bladder overactivity in SHR can be normalized by intrathecally, but not intra-arterially, administered a 1 -AR antagonists.
It is know that in bladder hypertrophy secondary to out¯ow obstruction, there may be increased afferent activity. 13 To test whether or not there was also a change in the central noradrenergic control of micturition, normal rats and rats with out¯ow obstruction undergoing continuous cystometry were given a 1 -AR antagonists intrathecally. 14 It could be shown that in normal animals, there was only a transient decrease in micturition pressure and no other changes in the urodynamic parameters measured. However, in the obstructed animals, there was a pronounced reduction of micturition pressure, and in some animals, dribbling incontinence could be induced.
Taken together, these results suggest that a 1 -AR antagonists may have a central site of action when modifying the micturition re¯ex. Although the a 1 -AR subtype implicated remains to be identi®ed, these central a 1 -ARs seem to have an increased role in bladder overactivity associated with out¯ow obstruction. Providing that these receptors can be selectively blocked in the absence of side effects of central origin, they may be an interesting target in the treatment of LUTS.
Penile erectile tissues
The genital tract is also under central and peripheral sympathetic noradrenergic control. 15 However, the involvement of central noradrenergic pathways for erectile responses and for sexual function have not been well established. In rats, a 1 -AR stimulation increases and a 2 -AR stimulation decreases sexual function. In humans, clonidine may cause impotence and decreased arousal, supporting the concept that a 2 -ARs are speci®cally involved in sexual arousal.
Much more is known about the function of the noradrenergic system in the corpus cavernosum (CC) and the penile vasculature. 15 To get an erection, it is necessary not only to release factors that relax the corporal smooth muscle and the penile vessels, but also to remove, or counteract the effects of, the contractile factors, e.g. NA. The penis has a very rich noradrenergic innervation. 16 Penile arteries and veins and CC smooth muscle all have an adrenergic nerve supply. The helicine vessels, in particular, are surrounded by a dense network of noradrenergic nerves, which is of higher density than in the CC.
It has been a matter of discussion as to whether the noradrenergic nerves contain other transmitters or transmitter generating enzymes, in particular, nitric oxide synthase (NOS). Tamura and co-workers 17 have shown that both cholinergic and noradrenergic nerves in the human penis contain NOS, and thus would be able to produce and release nitric oxide (NO). Confocal microscopy of the rat penis has clearly shown that tyrosine hydroxylase, a marker for adrenergic nerves, and NOS were contained within different nerves, even if the two types of nerve were laying very close together. 18 This was also con®rmed in human tissue. In contrast, NOS was colocalized with acetylcholine, as visualized using antibodies against the vesicular acetylcholine transporter protein (VAChT). The cholinergic nerves contain not only NOS, but also vasoactive intestinal peptide and pituitary adenylyl cyclase activating peptide, another vasodilator peptide. 19 When released, NA contracts the human CC by actions on postjunctional a 1 -as well as a 2 -ARs. 4 It is generally believed that a 1 -ARs are the most important for CC contraction. AR subtypes of a 1A , a 1B and a 1D have all been demonstrated in human corporal smooth muscle, 20 and functionally, also the a 1L -AR. 21 Which receptor subtype is of most importance in contraction is unclear, but a 1A -and/or a 1L -ARs seem to predominate, while a 1B -and a 1D -ARs play a minor role. 20, 21 Among the a 2 -AR subtypes, a 2A -, a 2B -, and a 2C -ARs have all been demonstrated, 22, 23 and it was recently suggested that the a 2A -AR was predominant. 23 In the penile vasculature, both a 1 -and a 2 -ARs can contribute to contractions, but a 2 -ARs may have a more important role than in the CC. Simonsen and colleagues 24 have suggested that NA stimulation of prejunctional a 2 -ARs may contribute to detumescence and¯accidity by inhibiting the release of NO. Since NOS is contained in cholinergic nerves, this would mean that these a 2 -ARs are located in cholinergic nerves.
Vas deferens
The noradrenergic innervation of the human vas deferen is very rich and concentrated in the circularly running smooth muscle layer, whereas the cholinergic nerves are concentrated near the lumen and mucosa. 25, 26 In vitro investigations of human vas deferens preparations have shown that phentolamine and prazosin are able to abolish electrically induced contractions. 27 It has been established that phenoxybenzamine may cause dry ejaculations. 28 ± 30 This could be explained either by retrograde ejaculation or by paralysis of the vas deferens circular smooth muscle and consequent inhibition of the propagating activity of the vas deferens. 28 Clonidine (a 2 -AR agonist) reduced electrically induced contractions by inhibiting the release of NA. Rauwolscine (a 2 -AR antagonist) in increasing concentrations had a double effect, initially increasing the contractile responses to electrical ®eld stimulation by increasing the release of NA, and at high concentrations inhibiting the responses by losing its selectivity and also blocking a 1 -ARs. 27 Thus, the postjunctional a 1 -ARs seem to be very important for contraction of the human vas deferens. The subtype mainly involved was shown to be the a 1A -or a 1A/L -ARs. 31, 32 Treatment of BPH patients with a 1 -AR antagonists with af®nity for the a 1 -ARs in the vas deferens may negatively affect its function and thereby ejaculation.
Conclusions
The sympathetic nervous system has an important role in the regulation of urogenital function. Among the adrenergic receptors involved in the sympathetic control of the lower urinary tract, a 1 -ARs appear to play a predominant role. Extraprostatic a 1 -ARs seem to be contributing to LUTS. Thus, when using a-AR antagonists to treat LUTS, it is important to broaden the focus to beyond the prostate. The role of a-ARs in the bladder in the pathogenesis of LUTS remains controversial. a 1 -AR antagonists may have a central site of action. These sites of action are worthy of further study. a 1 -AR antagonists can improve erectile function, although the receptor pro®le of an optimal drug remains to be established. Treatment with a 1 -AR antagonists with af®nity for a 1 -ARs in the vas deferens may negatively affect the function and thereby ejaculation. However, the overall effect of blockade of the a 1 -ARs in the course of treating pathological conditions of the lower urinary tract may contribute to the improvement of both micturition and sexual function.
